Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21554075 | 0.87 | CHRNB2 (0.43) | CHRNB2CHRNB4CHRNA4ALDH1A1PAOX | |
| SCHEMBL22336919 | 0.77 | ALDH1A1 (0.48) | CHRNB2CHRNB4CHRNA4ALDH1A1PAOX | |
| SCHEMBL20176417 | 0.72 | ALDH1A1 (0.43) | CHRNB2CHRNB4CHRNA4ALDH1A1PAOX | |
| SCHEMBL22851385 | 0.69 | ALDH1A1 (0.63) | ALDH1A1PAOX | |
| SCHEMBL25658866 | 0.69 | ALDH1A1 (0.47) | CHRNB2CHRNB4CHRNA4ALDH1A1PAOX | |
| SCHEMBL24246010 | 0.69 | CHRNB2 (0.52) | CHRNB2CHRNB4CHRNA4ALDH1A1HTT | |
| SCHEMBL22893451 | 0.68 | L3MBTL1 (0.38) | ALDH1A1HTT | |
| SCHEMBL18811589 | 0.68 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA4ALDH1A1 | |
| SCHEMBL25183111 | 0.67 | ALDH1A1 (0.48) | CHRNB2CHRNB4CHRNA4ALDH1A1 | |
| SCHEMBL22336918 | 0.66 | ALDH1A1 (0.39) | ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | BRCA1, ESR2, ESR1 | CHRNB2 3654/4885CHRNB4 4111/4885CHRNA4 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.